Merck and ICR enter renewed cancer drug discovery partnership

25 Sep 2023
www.pharmaceutical-technology.com
Vaccine
Merck and ICR enter renewed cancer drug discovery partnership
Preview
Source: Pharmaceutical Technology
Merck and ICR will provide staff and financial resources for the new multi-year partnership. Credit: Merck KGaA.
Merck KGaA (Merck) and the UK’s Institute of Cancer Research (ICR) have entered a renewed strategic collaboration to discover and develop new therapeutics for treating cancer.
Researchers at the institute’s Centre for Cancer Drug Discovery and Merck will join forces to develop small-molecule inhibitors of a new class of cancer targets.
Recommended Reports
Merck and ICR enter renewed cancer drug discovery partnership
Preview
Source: Pharmaceutical Technology
ReportsInnovation in pharma: cancer combination therapy GlobalData
Merck and ICR enter renewed cancer drug discovery partnership
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Vaccine For Oncology in Prostate Cancer GlobalData
View allCompanies IntelligenceMerck KGaAInstitute of Cancer ResearchICR Co., Ltd.View all
Both parties will provide staff and financial resources for the multi-target, multi-year partnership.
Merck will also provide funds for nine full-time research positions at the institute.
The latest deal is part of Merck and ICR’s strategy to bring innovation in the discovery of cancer therapies.
ICR Centre for Cancer Drug Discovery director and cancer therapeutics division head, Professor Olivia Rossanese, stated: “As ever we’ll be working together on a range of projects that combine our expertise in drug discovery with our deep biological insights into cancer, with a focus on discovering innovative small-molecule therapeutics.
“This new agreement demonstrates our commitment to translating our research programmes into the clinic in collaboration with industry partners – of whom we have more than 100 at the ICR – and ultimately to delivering new, life-saving treatments to cancer patients.”
In February 2018, the parties entered a similar collaboration for the discovery and development of cancer therapies, from target discovery to the preclinical drug candidate’s nomination stage.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.